The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640, Febuxostat and Colchicine interaction in patients with gout.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Maximun observed concentration (Cmax) of Febuxostat and Colchicine from plasma
PK profile
Time frame: Clinical significant changes from baseline up to Day 8
Area under the concentration-time curve (AUC) of Febuxostat and Colchicine from plasma
PK profile
Time frame: Clinical significant changes from baseline up to Day 8
Apparent terminal half-life (t1/2) of Febuxostat and Colchicine from plasma
PK profile
Time frame: Clinical significant changes from baseline up to Day 8
Incidence of Adverse events
Safety issue
Time frame: Clinical significant changes from Day-14 up to Day 16
Changes in Laboratory Values
Safety issue
Time frame: Clinical significant changes from Day-14 up to Day 16
Changes in Electrocardiogram
Safety issue
Time frame: Clinical significant changes from Day-14 up to Day 16
Changes in Vital Signs Parameters
Safety issue
Time frame: Clinical significant changes from Day-14 up to Day 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.